Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31040946 | 0.92 | GPR119 (0.48) | GPR119HRH3ALKCHEK2KDM1A | |
| SCHEMBL31255386 | 0.86 | DDB1 (0.45) | GPR119ALKDDB1CRBN | |
| SCHEMBL23120993 | 0.85 | GPR119 (0.54) | GPR119HRH3CHEK2KDM1ADDB1 | |
| SCHEMBL31040953 | 0.84 | KDM1A (0.52) | GPR119HRH3ALKCHEK2KDM1A | |
| SCHEMBL29264315 | 0.84 | DDB1 (0.53) | HRH3DDB1CRBN | |
| SCHEMBL31554643 | 0.81 | DDB1 (0.56) | GPR119HRH3ALKCHEK2KDM1A | |
| SCHEMBL31040950 | 0.81 | DDB1 (0.62) | GPR119KDM1ADDB1CRBN | |
| SCHEMBL30952388 | 0.80 | DDB1 (0.50) | GPR119DDB1CRBN | |
| SCHEMBL30830790 | 0.80 | DDB1 (0.55) | GPR119HRH3ALKCHEK2DDB1 | |
| SCHEMBL215713 | 0.79 | GPR119 (0.57) | GPR119HRH3ALKCHEK2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240261416-A1 | SYNTHESIS OF NOVEL CEREBLON E3 LIGASE LIGANDS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240261416-A1 | SYNTHESIS OF NOVEL CEREBLON E3 LIGASE LIGANDS, COMPOUNDS FORMED THEREBY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CRBN, CUL1, CUL5 | GPR119 1535/4885HRH3 1905/4885ALK 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.